Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY) stock analysis
ALNY · Alnylam Pharmaceuticals, Inc. - Common Stock
Latest recorded price: USD 159.73
Sector and industry: Healthcare · Biotechnology
A reliable intrinsic value could not be calculated for ALNY; the assessment relies on sector multiple comparisons. Fiscal 2025 figures: revenue growth 53.0%, free cash flow margin 12.5%. The model flags 1 risk signal for this company.
Similar companies in Healthcare
- AnaptysBio, Inc. - Common Stock (ANAB)
- Arrowhead Pharmaceuticals, Inc. - Common Stock (ARWR)
- Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
- Axsome Therapeutics, Inc. - Common Stock (AXSM)
- BridgeBio Pharma, Inc. - Common Stock (BBIO)
- Beam Therapeutics Inc. - Common Stock (BEAM)
- BioMarin Pharmaceutical Inc. - Common Stock (BMRN)
- Celldex Therapeutics, Inc. (CLDX)